RxSight, Inc. (NASDAQ:RXST) Shares Sold by Fmr LLC

FMR LLC cut its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 4.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,202,251 shares of the company's stock after selling 52,078 shares during the period. FMR LLC owned about 2.98% of RxSight worth $59,427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RXST. Brown Capital Management LLC purchased a new position in RxSight in the third quarter valued at $26,813,000. Marshall Wace LLP purchased a new position in RxSight in the second quarter valued at $19,512,000. Driehaus Capital Management LLC increased its holdings in RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock valued at $42,490,000 after buying an additional 302,367 shares in the last quarter. Baillie Gifford & Co. increased its holdings in RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company's stock valued at $21,554,000 after buying an additional 291,733 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new position in RxSight in the second quarter valued at $14,942,000. Hedge funds and other institutional investors own 78.78% of the company's stock.

RxSight Stock Performance

Shares of RXST stock traded up $0.87 on Friday, reaching $43.15. 584,486 shares of the company were exchanged, compared to its average volume of 666,124. RxSight, Inc. has a 1 year low of $33.09 and a 1 year high of $66.54. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -51.99 and a beta of 1.11. The business has a 50-day moving average price of $48.01 and a 200 day moving average price of $51.67.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and set a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, UBS Group initiated coverage on shares of RxSight in a research note on Friday. They set a "buy" rating and a $52.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight has a consensus rating of "Buy" and a consensus target price of $63.63.

Insider Activity at RxSight

In other RxSight news, Director Jesse Anderson Corley acquired 11,111 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average price of $45.37 per share, with a total value of $504,106.07. Following the purchase, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ilya Goldshleger sold 1,330 shares of the company's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90. Following the sale, the insider now directly owns 42,246 shares of the company's stock, valued at approximately $1,948,807.98. This represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,807 shares of company stock valued at $3,202,275. Corporate insiders own 9.36% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.